Market Access

A qualitative study explores how MA plan leaders, kidney care managers, and dialysis providers perceive the benefits, risks, and marketing practices surrounding MA enrollment for patients with end-stage kidney disease.

As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.

State Medicaid leaders create a plan to ensure safety, affordability, and equitable access for children and families living with rare diseases.

Analysis compares care quality and efficiency within physician groups that treat Medicare Advantage patients under at-risk contracts, versus fee-for-service.

When automatically moved from a zero-dollar silver plan to one that requires a premium due to plan turnover, do lower-income health insurance marketplace enrollees lose or switch coverage?

A cross-sectional study investigates whether becoming eligible for Medicare at age 65 is linked to changes in healthcare use among individuals experiencing mental health challenges.

Is Medicare plan switching influenced by initial type of Medicare coverage and cancer history?

Though this specific agreement centers around aerospace and automobiles, the greater supply chain will wait and see how Trump’s import taxes impact pharmaceuticals, a sector that faces a potential 25% tax on imports.

An exploration into how flawed incentives and contractual loopholes between manufacturers and pharmacy benefit managers played their part.

How practical is this form of pricing in the pharma setting?

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

A cross-sectional study explores how full-benefit dual-eligible beneficiaries differ across MA plans with differing levels of Medicaid coordination and integration.

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ‘foundational immuno-oncology backbone.’

An NEJM study explores how this loss—following Medicaid disenrollment—affects beneficiaries.

Andrew Witty resigns due to personal reasons, as Stephen Hemsley, chairman and former chief executive, will assume the position.

Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement challenges, shifting distribution models, and expanding the drugs’ potential into new therapeutic areas.

Fran Gregory, VP, emerging therapies, Cardinal Health, emphasizes the need for long-term outcomes tracking and robust health economic modeling to demonstrate the sustained value of advanced therapies and support future payment strategies.

Chip Parkinson, CEO, GiftHealth, explains how AI-powered data integration is bringing new hope to patients by revealing hidden access barriers, streamlining treatment pathways, and challenging outdated utilization management practices.

Tiara Green, president, Accessia Health, explains how empowering trusted local leaders and involving communities early are key to closing persistent gaps in preventive care and healthcare access.

Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.

A seminar shares key observations and learnings from the first round of direct price negotiations.

Tiara Green, president, Accessia Health, highlights key themes from the upcoming discussion on how health equity, literacy, and social determinants are reshaping patient care—especially for those with chronic and rare conditions.

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug development landscape.

The interchangeability designation for Yuflyma, a biosimilar to Humira, may help to improve patient access and reduce costs.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chris O’Dell, provides an update on where the healthcare industry currently stands in terms of compliance with price transparency regulations, and what steps need to be taken to achieve full compliance.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chris O’Dell, Turquoise Health’s SVP of market solutions, discusses the biggest challenges healthcare organizations currently face in terms of price transparency.

The key strategies for reducing or eliminating post-prescription abandonment.

A look at the prevailing factors impacting treatment access in 2025.

How pharma manufacturers can steadily navigate GTN components and complexities when planning pharmacy benefit reimbursement.